Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, alleging that the company misled investors regarding its business operations and regulatory prospects [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Atara Biotherapeutics made false and misleading statements about its manufacturing issues and the regulatory prospects of its tabelecleucel Biologics License Application (BLA), which were overstated [2]. - Specific allegations include that manufacturing deficiencies and issues with the ALLELE study made FDA approval unlikely, and these problems heightened regulatory scrutiny and jeopardized ongoing clinical trials [2]. - The lawsuit asserts that these misrepresentations had a significant negative impact on Atara's business and financial condition, leading to investor damages when the truth was revealed [2]. Group 2: Participation and Legal Representation - Shareholders wishing to act as lead plaintiffs in the class action must file motions with the court by May 22, 2026, and do not need to participate in the case to be eligible for recovery [2]. - Rosen Law Firm operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless they recover losses [3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Picard Medical, Inc. for allegedly misleading investors regarding its business operations during the specified Class Period from September 2, 2025, to October 31, 2025 [1][2]. Allegations - The lawsuit claims that Picard Medical made materially false and misleading statements and failed to disclose significant adverse facts about its business and operations [3]. - Specific allegations include: 1. Involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals [3]. 2. Insiders and affiliates allegedly used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [3]. 3. Public statements and risk disclosures from Picard omitted any mention of false rumors and artificial trading activity affecting stock prices [3]. 4. Positive statements made by the defendants regarding Picard's business and prospects were materially misleading and lacked a reasonable basis [3]. Participation in Class Action - Investors may be eligible to participate in the class action against Picard Medical, with a lead plaintiff representing other class members [4]. - Shareholders do not need to actively participate in the case to be eligible for recovery, and all representation is on a contingency fee basis, meaning no fees or expenses are incurred by shareholders [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its active role in securities class actions and has successfully recovered over $1 billion for shareholders since its inception [5].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against F5, Inc. for allegedly misleading investors about its business operations and financial outlook during the specified class period from October 28, 2024, to October 27, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that F5, Inc. misrepresented its revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [3]. - It is alleged that F5's optimistic statements regarding its security capabilities were misleading, as the company was experiencing a significant security incident that jeopardized both client security and F5's future prospects [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file motions with the court by February 17, 2026, and can choose to remain absent class members without participating in the case [4]. - The representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [5]. Group 3: About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].